Natriumjodid (I-131) Ge Healthcare (Sodium Iodide (131i))

Sodium Iodide I-131, the active ingredient in Natriumjodid (I-131), is a radioactive iodine presented as a radiopharmaceutical for oral use. It is employed in diagnostic imaging and therapeutic ablation of thyroid tissue, primarily in patients with thyroid disorders such as hyperthyroidism or differentiated thyroid cancer.

GNH USA supplies Natriumjodid (I-131) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Natriumjodid (I-131) is used in the management of thyroid‑related conditions where radioactive iodine uptake is required. - Thyroid imaging: enables visualization of thyroid tissue distribution for diagnostic assessment. - Thyroid ablation: delivers localized radiation to destroy overactive or residual thyroid cells after surgery. - Treatment of hyperthyroidism: reduces hormone production by selectively irradiating hyperfunctioning thyroid tissue.

Adverse reactions may occur following oral administration of radioactive iodine.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Dry mouth: reduced salivary flow after uptake. - Taste alteration: temporary metallic or bitter taste sensation. - Fatigue: transient tiredness during the first few days. - Mild thyroid pain: localized discomfort in the neck region.

Serious or Rare Side Effects: - Salivary gland inflammation: painful swelling requiring medical attention. - Severe allergic reaction: rash, itching, or anaphylaxis. - Bone marrow suppression: rare decrease in blood cell counts. - Pulmonary fibrosis: extremely rare lung tissue scarring. - Secondary malignancy: long‑term risk of radiation‑induced cancers.

Use of Natriumjodid (I-131) requires careful consideration of patient factors and handling procedures. - Pregnancy: avoid use unless clearly needed, as fetal thyroid can be affected. - Breastfeeding: discontinue breastfeeding for an appropriate period after administration. - Renal impairment: adjust monitoring as reduced clearance may increase exposure. - Thyroiditis: assess risk of exacerbating inflammation. - Radiation safety: follow local regulations for handling and disposal of radioactive material. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Radioactive iodine can interact with other agents that affect iodine metabolism or radiation exposure.

Major Interactions (Avoid): - Antithyroid drugs (e.g., methimazole, propylthiouracil): may block iodine uptake, reducing efficacy. - High‑dose potassium iodide: competitively inhibits sodium‑iodide symporter, diminishing uptake.

Moderate Interactions (Monitor Closely): - Lithium: can alter thyroid function and iodine handling, requiring thyroid function monitoring. - Amiodarone: contains large iodine load, may interfere with radioiodine distribution. - Diuretics: may affect renal clearance of iodine, necessitating dose adjustment.